{"news_desk": "Business", "print_page": "", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By CHAD BRAY", "person": [{"rank": 1, "role": "reported", "firstname": "Chad", "organization": "", "lastname": "BRAY"}]}, "abstract": null, "type_of_material": "News", "word_count": "138", "lead_paragraph": "Under the deal, Bavarian Nordic could receive as much as $975 million to license its advanced prostate cancer treatment, Prostvac.", "pub_date": "2015-03-05T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Bristol-Myers Squibb Enters Drug Licensing Deal With Danish Biotechnology Firm"}, "snippet": "Under the deal, Bavarian Nordic could receive as much as $975 million to license its advanced prostate cancer treatment, Prostvac.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/03/05/business/dealbook/bristol-myers-squibb-enters-drug-licensing-deal-with-danish-biotechnology-firm.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Bristol Myers Squibb Company", "name": "organizations"}, {"rank": "2", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Prostate Cancer", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Clinical Trials", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Denmark", "name": "glocations"}, {"rank": "6", "is_major": "N", "value": "Bavarian Nordic AS", "name": "organizations"}], "blog": [], "_id": "54f7c52638f0d8579fff5f51", "source": "The New York Times"}